ArticleFrontiers in neurology2019
Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis.
Article in Frontiers in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review.Frontiers in neurology · 2021Pooled it
- Assessment of brain atrophy as a promising marker of radiological activity in patients with relapsing-remitting multiple sclerosis.Frontiers in neuroscience · 2025Article
- Patients with relapsing-remitting multiple sclerosis show accelerated whole brain volume and thalamic volume loss early in disease.Neuroradiology · 2025Article
- A systematic literature review of the association between global brain atrophy and the Expanded Disability Status Scale score in people with multiple sclerosis.Therapeutic advances in neurological disorders · 2025Review
- AI-driven MRI analysis reveals brain atrophy patterns in benign relapsing-remitting multiple sclerosis.Frontiers in neurology · 2025Article
- Assessing disease progression and treatment response in progressive multiple sclerosis.Nature reviews. Neurology · 2024Review
- Automated magnetic resonance imaging quantification of cerebral parenchymal and ventricular volume following subarachnoid hemorrhage: associations with cognition.Brain imaging and behavior · 2024Article
- Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis.International journal of molecular sciences · 2023Review
- Neurodegeneration in multiple sclerosis.WIREs mechanisms of disease · 2023Review
- Neurodegeneration and its potential markers in the diagnosing of secondary progressive multiple sclerosis. A review.Frontiers in molecular neuroscience · 2023Review
- Grey matter atrophy in patients with benign multiple sclerosis.Brain and behavior · 2022Article
- Predictive MRI Biomarkers in MS-A Critical Review.Medicina (Kaunas, Lithuania) · 2022Review
- Sex bias in multiple sclerosis and neuromyelitis optica spectrum disorders: How it influences clinical course, MRI parameters and prognosis.Frontiers in immunology · 2022Review
- Characterization of thalamic lesions and their correlates in multiple sclerosis by ultra-high-field MRI.Multiple sclerosis (Houndmills, Basingstoke, England) · 2021Article
- Identifying Early Neuropsychological Indicators of Cognitive Involvement in Multiple Sclerosis.Neuropsychiatric disease and treatment · 2021Review
- Intrinsic and Extrinsic Mechanisms of Thalamic Pathology in Multiple Sclerosis.Annals of neurology · 2020Article
- Aggressive multiple sclerosis (1): Towards a definition of the phenotype.Multiple sclerosis (Houndmills, Basingstoke, England) · 2020Article
- Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple Sclerosis.Frontiers in neurology · 2020Article
- Age-dependent cut-offs for pathological deep gray matter and thalamic volume loss using Jacobian integration.NeuroImage. Clinical · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.